These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36526163)

  • 21. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there an optimal factor structure of the Positive and Negative Syndrome Scale in patients with first-episode psychosis?
    Langeveld J; Andreassen OA; Auestad B; Færden A; Hauge LJ; Joa I; Johannessen JO; Melle I; Rund BR; Røssberg JI; Simonsen E; Vaglum P; Larsen TK
    Scand J Psychol; 2013 Apr; 54(2):160-5. PubMed ID: 23252448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
    O'Gorman C; Kapur S; Kolluri S; Kane J
    Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
    Volavka J; Czobor P; Citrome L; McQuade RD; Carson WH; Kostic D; Hardy S; Marcus R
    J Clin Psychiatry; 2005 Nov; 66(11):1362-6. PubMed ID: 16420071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
    Feldman PD; Kaiser CJ; Kennedy JS; Sutton VK; Tran PV; Tollefson GD; Zhang F; Breier A
    J Clin Psychiatry; 2003 Sep; 64(9):998-1004. PubMed ID: 14628974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
    von Knorring L; Lindström E
    Acta Psychiatr Scand; 1992 Dec; 86(6):463-8. PubMed ID: 1281960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
    Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The heterogeneity of antipsychotic response in the treatment of schizophrenia.
    Case M; Stauffer VL; Ascher-Svanum H; Conley R; Kapur S; Kane JM; Kollack-Walker S; Jacob J; Kinon BJ
    Psychol Med; 2011 Jun; 41(6):1291-300. PubMed ID: 20925971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
    Stefanovics EA; Krystal JH; Rosenheck RA
    Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial.
    Ryan A; Baker A; Dark F; Foley S; Gordon A; Hatherill S; Stathis S; Saha S; Bruxner G; Beckman M; Richardson D; Berk M; Dean O; McGrath J; Group CW; Scott J
    Trials; 2017 Apr; 18(1):165. PubMed ID: 28388932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Audio-digital recordings to assess ratings reliability in clinical trials of schizophrenia.
    Targum SD; Pendergrass JC; Murphy C
    Schizophr Res; 2021 Jun; 232():54-60. PubMed ID: 34015556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Yoruba version of the Beck Hopelessness Scale: psychometric characteristics and correlates of hopelessness in a sample of Nigerian psychiatric outpatients.
    Aloba O; Akinsulore A; Mapayi B; Oloniniyi I; Mosaku K; Alimi T; Esan O
    Compr Psychiatry; 2015 Jan; 56():258-71. PubMed ID: 25446724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial.
    Pagsberg AK; Krogmann A; Jeppesen P; von Hardenberg L; Klauber DG; Jensen KG; Rudå D; Decara MS; Jepsen JRM; Fagerlund B; Fink-Jensen A; Correll CU; Galling B
    J Am Acad Child Adolesc Psychiatry; 2022 Aug; 61(8):997-1009. PubMed ID: 35026408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials.
    Hieronymus F; Correll CU; Østergaard SD
    Transl Psychiatry; 2023 Jun; 13(1):191. PubMed ID: 37286548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia.
    Nielsen CM; Kølbæk P; Dines D; Pedersen ML; Danielsen AA; Holmgård C; Wissing S; Esbøl AM; Fuglsang NFB; Nguyen TD; Mors O; Opler M; Correll CU; Østergaard SD
    J Psychopharmacol; 2022 Nov; 36(11):1208-1217. PubMed ID: 36268705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.